Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.